MedTrace Logo

Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly

NCT04139915 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2019-11-22

No results posted yet for this study

Summary

The purpose of this study is to determine if RTB101 prevents illness associated with respiratory tract infections in people ≥65 years of age.

Conditions

  • Clinically Symptomatic Respiratory Illness

Interventions

DRUG

Dactolisib

TORC1 inhibitor

DRUG

Placebo

Placebo capsule

Sponsors & Collaborators

  • Restorbio Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Restorbio Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-21
Primary Completion
2019-11-15
Completion
2019-11-15
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04139915 on ClinicalTrials.gov